Table III.
Some Examples of Pharmacological Targets Within the CNS
| Assumed (predominant-) target | Mechanism of action | Example(s)of compounds (late-stage development or approved) |
|---|---|---|
| Dopamine/norepinephrine/serotonina | Inhibition of uptake | Subitramine |
| Bupropion | ||
| Tesofensine | ||
| Stimulation of release | Phentermine | |
| GABA | Stimulation of GABA activityb | Topiramate (in combinations)b |
| Zonisamide (in combinations)b | ||
| Serotonin-receptor (5-HT2c) | Agonist | Lorcaserin |
| Serotonin-receptor (5-HT6) | Agonist | Several compounds in early clinical phase |
| MC4-receptor | Agonist | Preclinical/early clinical |
| MCH-receptor type 1 | Antagonist | NGD-4715 |
| Histamine (H3-) receptor | Antagonist | Preclinical and early clinical phase |
| NPY (Y5) receptor | Antagonist | Velneperit |
| AgRP | Inhibition | TTP435 |
| PTP1B | Inhibition | Trodusquemine |
aoften affecting different neurotransmitters with different relative potency
bcombined with other mechanisms, partly unresolved